Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4
Binghe Xu, Xichun Hu, Wěi Li, Tao Sun, Kunwei Shen, Shusen Wang, Ying Cheng, Qingyuan Zhang, Shude Cui, Zhongsheng Tong, Cuizhi Geng, Erwei Song, Chiun‐Sheng Huang, Virote Sriuranpong, Roger K.C. Ngan, Yee Hong Chia, Xinwei Wang, Huadong Zhao
Topics & Concepts
LetrozolePalbociclibHuman Epidermal Growth Factor Receptor 2Breast cancerOncologyMedicineInternal medicinePlaceboPostmenopausal womenOestrogen receptorEstrogen receptorGynecologyCancerTamoxifenMetastatic breast cancerPathologyAlternative medicineAdvanced Breast Cancer TherapiesBreast Cancer Treatment StudiesCancer-related Molecular Pathways